-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Source: Guanlan Pharmaceutical
According to the latest announcement on the website of China's State Food and Drug Administration, the carfilzomib for injection (carfilzomib, trade name: Kyprolis) jointly developed by Amgen and BeiGene has been officially approved in China
Screenshot source: reference [1]
Proteasomes (proteasomes) in cells can break down damaged or no longer needed proteins, which play an important role in the normal function and growth of cells
In 2016, carfilzomib was approved by the US FDA as a monotherapy or a combination therapy with dexamethasone or dexamethasone + lenalidomide to treat patients with relapsed or refractory MM
In a phase 3 clinical trial called ASPIRE, 792 patients with relapsed or refractory MM received carfilzomib combined with lenalidomide and dexamethasone (KRd) combination regimen or lenalidomide and dexamethasone (Rd) regimen
The test results showed that the average OS of the patients receiving KRd therapy was 48.